Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hello, anybody out there!!
I think SA has eluded to the fact he has learnt his lesson on this in one of the interviews. I believe he said he would insert clauses meaning payments for extensions too.
I would definitely be stipulating an upfront for any further projects considering how they strung us along on this first one!
I suspect a follow on project involving both the lysate and additional ingredients informed by the inflammation study outcome will be announced next year for sunscreen that is if Croda have not bought Skin out by then. "The inflammation study is also progressing well. It is looking at how the microbiome can influence and balance the body's response to inflammation specifically related to harmful UVR (sunlight) light. The aim is to advance these findings to be tested on human skin. The programme will run until June 2025. "
Alex has gone rogue exploring EU regs and UV protection potential. He is making a point and a stance I think we should pay attention to, IMHO.
Hailed as the secret to great skin, this derivative of vitamin A has been championed by countless brands, beauty buffs, and influencers. Yet, the skincare landscape is shifting, and a new contender is emerging to challenge Retinol's reign. Enter SkinBioTherapeutics' lysate technology, a scientifically-backed, clinically-proven innovation poised to disrupt the market – especially in light of the European Union Commission’s new restrictions on retinol concentrations.
Imagine the possibilities; Sederma's expertise in developing active ingredients, combined with SkinBioTherapeutics' lysate technology, could lead to cutting-edge UV protection formulations.
https://open.substack.com/pub/lemminginvestor/p/skinbiotherapeutics-plc-974?r=kcv2o&utm_medium=ios
Indeed! Kevin
Excellent work Aquae and diligently put together. Not long now until this should all be out in the open. Fingers crossed SA recognises the gaps in knowledge that may have arisen for even keen LTH such as myself, as you have done, and provides answers suitable to clearly restate the case of the company and its technology as an investment proposition. After all, it has been a looooooong time coming since those heady days of 75p when we were led to expect a flood of imminent opportunity. When listening to SA in any presentation or interview, and when reading your latest summary, I see no reason why this is still not the case. My groundworks comments come because the SP is telling us the market is at the end of its tether in terms of realisation of some of the opportunities.
Clio, during the last TW paid for interview before the Bromance with SA ended, Stuart mentioned that they were talking to Croda about other Projects, so the groundwork is there. That said, the clinical trials carried out by Croda are purely focused on the Cosmetic market, sunscreen and medicated shampoo are classed as medical not cosmetics and Stuart has confirmed are not covered by the current Croda license. So what are these new and additional scientific claims being substantiated? I looked back at the original Apr 2019 Study Results RNS where 3 measures of the Skin Barrier took place. Firstly Corneometry which measures how hydrated the skin is. Secondly, Transepidermal Water Loss, a measure of water loss through the skin. Thirdly, Skin Elasticity. The first two measures produced significant statistical reductions using the lysate which differed in speed of response across age groups. However, the third measure showed no improvement in elasticity. Yet going back to Oct 21 during the Investor Meets, we were told that skinbiotix increases the elastic fibres in skin, so what led to this claim? Coincidently, the Skinbiotix Pillar report in the Nov 21 Final Results RNS reported then that sederms had identified additional potential scientific and marketing claims during scale-up, so might elasticity be one such measure being clinically proven? Note measures 1 and 2 are focused on the outer layers of the skin barrier whilst measure 3 involves the middle layer of the skin barrier
Bit of clarifying info on the Acne Results courtesy of a response from SA to a question I posed via Elric's good offices. Q. "In the 5th Sep RNS it was stated that two different formulas would be trilled side by side, did this happen and if so did one perform better than the other"?
A. "We had 225 people in 2 separate groups made up of 3 cohorts starting at different times. There were 2 different formulations, Formula 1 (lead formula) is the one we have reported on as Formula 2 was nowhere near as successful and that is why the number is 93 at the final count".
My observation is this explains the Final RNS comment that "we still have some work to do on end formulation but our focus is very much on end commercialisation". There is no doubt as much was learnt about the actives in Formula 2 that did not work as well to help pinpoint the actives to focus on in the lead formulation.
Oleric
Your in out your in out,
you shake it about,
You do the Oki poki you turn around,
That's what it's all about.
You invested in this company recently, rather desperately and without much confidence?
You sound like a used car salesman’s dream.
"And more opportunities for the lysate?"
Is this guy totally deluded? Why people follow him is totally beyond me.He spouts utter rubbish in my opinion.
As people know I have followed and invested in this company for years.Recently rather desperately without much confidence.This company is going nowhere with promise after promise falling by the wayside .Everywhere you look you can find commercialised monetised bacteria treating each and every condition skin or otherwise.What has this to offer above and beyond all the others.?Attempts to actually sell a product have been pathetic but we have been led to believe otherwise many times.In my view its going down the pan and some of my money has gone with it.Everything now tells me this is going to end badly.The company bigwigs will walk away with their inflated salaries and soon after join another company and off we go again.The rampers on here will claim they sold at a profit and the ordinary Joe will be explaining to their family why there is no money! That's my prediction from a lot of knowledge and a lot of experience.Of course you could listen to a second hand car salesmen for advice,I am sure there will be several on here.
We have long had information that the lysate is a bit of a Swiss Army knife for repairing and protecting skin, opportunities have long been aplenty. I recognise we have been waiting for Croda to finish their work so the manufacturing begins, but I sincerely hope groundwork has been laid for various offshoots of commercialisation since as far back as the Manchester meet when we were told of the potential within.
And more opportunities for the lysate?
https://www.manxradio.com/news/uk-business/popular-sunscreens-fail-safety-test-as-and1632-49-rival-passes-with-flying-colours/
What a selling point for Croda, they also will be acutely aware of the results from the acne trial.
Seams like skinbiotix introduction will ne timed perfectly to enable companies to comply with the new EU law restricting t g e amount of retinol considered safe in skin products.https://www.independent.co.uk/extras/indybest/fashion-beauty/beauty/eu-retinol-ban-b2511235.html
This company IMO is going no where because of its terrible leadership by SA, his failed promises have lost a lot of people money he just and never had the skills of a CEO. The share price languishes at 10p, it will never see higher because of him
Disco, no it will not be happening anytime soon. SA has stated he wants to negotiate from a position of strength, so before any negotiations start I would suggest we focus on clearing the CB, get the Modi forecasts and Croda forecast, then hopefully we will be in a position of strength.
Disco I’d suggest it depends on how much of what SA has previously said is hard fact and what is exaggeration. We have previously been told there are multiple interested parties, which would usually mean at least one would be trying to close a deal fast to beat the competition. I doubt SA would be the one holding a deal off particularly given the SP decline over the last few years. It has been said for a long time the multinationals, plural, need to see that SBTX is not a one trick pony. The acne study proves this along with the Psoriasis product and the ongoing successful work with Croda and with the oral and inflammation research.
I wouldn’t expect SA to have a deal sewn up too soon, it will be fairly complicated and we already know these things take time. What I would certainly expect is for SA to let us know in his IMC presentation is what the reasonable next steps are to successfully commercialising the product and bringing in revenue to SBTX. Has a partner been selected/ how far on are the discussions/ has a structure and any numbers been discussed, and eventually, some forecasts, which any large company taking a whole pillar should be able to provide in advance. In fact, SA would be crazy to do a deal for such a large chunk of the company’s prospects without studying said forecasts. Fingers crossed we’ll know most of the above in the next 10 days.
Now we have the results of the acne trial, we are no longer a 'one-trick pony'.
We know that skin can't afford to market this product to its full potential, and it has been said before that a multinational would be interested in our products, especially if there is more than one, and acne is a huge market globally. So you would think someone has to be interested.
If a deal was to happen, could it be happening soon? I would presume the potential partner would have been waiting on these results. What do you all think?
Thinking our product treat the cause from within. Steroid cream and tablets commonly prescribed to treat the condition of bad skin. Its just what most doctors do not saying its right.
Steroids are indeed sometimes used to suppress very inflamed acne spots but use is very short term.They do not treat the condition as such and I would stick with my view that use of steroids for acne is quite unusual and Im not sure if any of the steroid creams has acne as a treatment indication but I could be wrong.
In other words it's a very decent outcome from the study. I'm sure steroid creams are and have been used for acne. All in all what's not to like?
As presented the results of this study are interesting enough and I have to say promising and suggest this product may help acne.Its good enough to provide enough evidence to support the promotion of axisbiotix for skin conditions.
Some caveats
As previously mentioned this was not a double blind study and some results were leaked and hyped half way through the study which is a bit odd given that it was run by an independent study company.This was not mentioned in the report produced in the RNS.No mention of statistical significance in the study report.Steroid creams were mentioned but it would be unusual to use steroid creams in the treatment of acne.
In summary the study is useful and indicates that this product may be a useful treatment for acne but contrary to some comments on here does not provide proof of efficacy.
You may be madabouttech but know nothing about science and studies.
An unblinded study with some results released during the study does not prove anything.
I will have a look at the results and give an independent study appraisal on here soon.